GEA
NVAX icon

Glen Eagle Advisors’s Novavax NVAX Stock Holding History

Glen Eagle Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60
Closed -$617 – 1174
2022
Q4 		$617 Hold
60
– – ﹤0.01% 1060
2022
Q3 		$1.09K Hold
60
– – ﹤0.01% 962
2022
Q2 		$3.09K Hold
60
– – ﹤0.01% 774
2022
Q1 		$4.42K Hold
60
– – ﹤0.01% 729
2021
Q4 		$8.58K Hold
60
– – ﹤0.01% 645
2021
Q3 		$12.4K Hold
60
– – ﹤0.01% 657
2021
Q2 		$12.7K Hold
60
– – ﹤0.01% 646
2021
Q1 		$10.9K Sell
60
-20
-25% -$3.98K ﹤0.01% 652
2020
Q4 		$8.92K Hold
80
– – ﹤0.01% 654
2020
Q3 		$8.67K Sell
80
-20
-20% -$2.44K ﹤0.01% 620
2020
Q2 		$8.34K Buy
+100
New +$3.83K ﹤0.01% 593

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glen Eagle Advisors's NVAX Position: Q1 2023 in Review

Glen Eagle Advisors sold out of Novavax (NVAX) in Q1 2023, closing a stake of 60 shares — an estimated $617 sold.

Glen Eagle Advisors first reported a position in NVAX in Q2 2020 and held it in 11 quarters. The position peaked at $12.7K in Q2 2021. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • Glen Eagle Advisors reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • Glen Eagle Advisors sold 60 Novavax shares in Q1 2023, an estimated $617.
  • Glen Eagle Advisors first reported a position in Novavax in Q2 2020 and held it in 11 quarters.
  • Glen Eagle Advisors's Novavax position peaked at $12.7K in Q2 2021.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Glen Eagle Advisors's 13F filing for Q1 2023, filed 13 Aug 2024.